Journal of Antimicrobial Chemotherapy (1999) 43, 523-527
© 1999 The British Society for Antimicrobial Chemotherapy
Continuous infusion versus intermittent administration of meropenem in critically ill patients
a Department of Internal Medicine I, Division of Infectious Diseases b Department of Internal Medicine I, Intensive Care Unit c Department of Laboratory Medicine, University of Vienna, Waehringer Guertel 18- 20, A-1090 Vienna, Austria
This prospective crossover study compared the pharmacokinetics of meropenem by continuous infusion and by intermittent administration in critically ill patients. Fifteen patients were randomized to receive meropenem either as a 2 g iv loading dose, followed by a 3 g continuous infusion (CI) over 24 h, or by intermittent administration (IA) of 2 g iv every 8 h (q8h). Each regimen was followed for a period of 2 days, succeeded by crossover to the alternative regimen for the same period. Pharmacokinetic parameters (mean ± SD) of CI included the following: concentration at steady state (CSS) was 11.9 ± 5.0 mg/L; area under the curve (AUC) was 117.5 ± 12.9 mg/L·h. The maximum and minimum serum concentrations of meropenem (C max, Cmin) and total meropenem clearance (Cl tot) for IA were 110.1 ± 6.9 mg/L, 8.5 ± 1.0 mg/L and 9.4 ± 1.2 L/h, respectively. The AUC during the IA regimen was larger than the AUC during CI (P< 0.001). In both treatment groups, meropenem serum concentrations remained above the MICs for the most common bacterial pathogens. We conclude that CI of meropenem is equivalent to the IA regimen and is therefore suitable for treating critically ill patients. Further studies are necessary to compare the clinical effects of CI and IA in this patient group.
* Corresponding author. Tel: +43-1-40400-4440; Fax: +49-89-66617-18696; E-mail: florian.thalhammer{at}akh-wien.ac.at
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Roberts, C. M. J. Kirkpatrick, M. S. Roberts, T. A. Robertson, A. J. Dalley, and J. Lipman Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution J. Antimicrob. Chemother., July 1, 2009; 64(1): 142 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. I. Siempos, K. Z. Vardakas, K. G. Manta, and M. E. Falagas Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia Eur. Respir. J., March 1, 2007; 29(3): 548 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Li, J. L. Kuti, C. H. Nightingale, and D. P. Nicolau Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J. Clin. Pharmacol., October 1, 2006; 46(10): 1171 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lorente, L. Lorenzo, M. M Martin, A. Jimenez, and M. L Mora Meropenem by Continuous Versus Intermittent Infusion in Ventilator-Associated Pneumonia due to Gram-Negative Bacilli Ann. Pharmacother., February 1, 2006; 40(2): 219 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Krueger, J. Bulitta, M. Kinzig-Schippers, C. Landersdorfer, U. Holzgrabe, K. G. Naber, G. L. Drusano, and F. Sorgel Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1881 - 1889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jaruratanasirikul, S. Sriwiriyajan, and J. Punyo Comparison of the Pharmacodynamics of Meropenem in Patients with Ventilator-Associated Pneumonia following Administration by 3-Hour Infusion or Bolus Injection Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1337 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Lomaestro and G. L. Drusano Pharmacodynamic Evaluation of Extending the Administration Time of Meropenem using a Monte Carlo Simulation Antimicrob. Agents Chemother., January 1, 2005; 49(1): 461 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Kuti, P. K. Dandekar, C. H. Nightingale, and D. P. Nicolau Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem J. Clin. Pharmacol., October 1, 2003; 43(10): 1116 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jaruratanasirikul and S. Sriwiriyajan Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection J. Antimicrob. Chemother., September 1, 2003; 52(3): 518 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Viaene, H. Chanteux, H. Servais, M.-P. Mingeot-Leclercq, and P. M. Tulkens Comparative Stability Studies of Antipseudomonal {beta}-Lactams for Potential Administration through Portable Elastomeric Pumps (Home Therapy for Cystic Fibrosis Patients) and Motor-Operated Syringes (Intensive Care Units) Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2327 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. de Stoppelaar, L. Stolk, F. van Tiel, A. Beysens, S. van der Geest, and P. de Leeuw Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia J. Antimicrob. Chemother., July 1, 2000; 46(1): 150 - 151. [Full Text] [PDF]
|
|